Community-Acquired Pneumonia (CAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Community-Acquired Pneumonia (CAP) Market Outlook

Thelansis’s “Community-Acquired Pneumonia (CAP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Community-Acquired Pneumonia (CAP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Community-Acquired Pneumonia (CAP) Overview

Community-acquired pneumonia (CAP) denotes an acute infection affecting the pulmonary parenchyma in individuals devoid of recent hospitalization within 14 days and not residing in nursing homes or long-term care facilities. The etiology of CAP encompasses two broad categories: Typical agents (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Group A Streptococci, anaerobes, and gram-negative organisms) and Atypical agents (e.g., Legionella, Mycoplasma, Chlamydia pneumoniae, and C. psittaci), with H. influenzae and S. pneumoniae commonly implicated as bacterial causative agents. Pharyngeal colonization by pathogens, followed by micro-aspiration, constitutes the primary mechanism of lower respiratory tract invasion, supplemented by hematogenous dissemination and macro-aspiration. Pneumonia manifests when host pulmonary defenses are compromised or overwhelmed by a substantial pathogen inoculum or virulence. Risk factors for CAP encompass advancing age, chronic comorbidities, notably chronic obstructive pulmonary disease (COPD), chronic lung diseases (e.g., bronchiectasis, asthma), chronic heart diseases (particularly congestive heart failure), stroke, diabetes mellitus, malnutrition, and immunocompromising conditions. Viral respiratory tract infections, especially influenza, predispose individuals to primary viral pneumonia and secondary bacterial pneumonia. Impaired airway protection, exemplified by conditions fostering microaspiration of gastric contents or microaspiration of upper airway secretions (e.g., altered consciousness, dysphagia), heightens CAP susceptibility. Modifiable behavioral risk factors include smoking, excessive alcohol consumption, and opioid use. In contrast, socio-environmental factors such as crowded living conditions, low-income settings, and exposure to environmental toxins also contribute to increased CAP risk. The therapeutic approach for outpatient CAP typically involves monotherapy with a macrolide (e.g., erythromycin, azithromycin, or clarithromycin) or doxycycline. However, in the presence of comorbidities such as chronic heart disease (excluding hypertension), chronic lung disease (including COPD and asthma), chronic liver disease, chronic alcohol use disorder, diabetes mellitus, smoking, splenectomy, human immunodeficiency virus (or other forms of immunosuppression), a respiratory fluoroquinolone (e.g., high-dose levofloxacin, moxifloxacin, gemifloxacin) or a combination of oral beta-lactam (e.g., high-dose amoxicillin or amoxicillin-clavulanate, cefuroxime, cefpodoxime) and macrolide is recommended.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Community-Acquired Pneumonia (CAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034